Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.750
+0.040 (2.34%)
At close: May 28, 2026, 4:00 PM EDT
1.770
+0.020 (1.14%)
After-hours: May 28, 2026, 5:06 PM EDT

Aldeyra Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
7.749.611.8913.3415.3711.28
Research & Development
20.6525.6648.2229.4647.3144.94
Total Operating Expenses
28.3835.2760.1242.7962.6856.22
Operating Income
-28.38-35.27-60.12-42.79-62.68-56.22
Interest Income
2.913.326.197.322.350.19
Interest Expense
-1.89-1.91-1.93-2.07-1.69-1.74
Total Non-Operating Income (Expense)
1.011.424.275.250.66-1.56
Pretax Income
-27.37-33.85-55.85-37.54-62.02-57.78
Net Income
-27.37-33.85-55.85-37.54-62.02-57.78
Net Income to Common
-27.37-33.85-55.85-37.54-62.02-57.78
Shares Outstanding (Basic)
606059595854
Shares Outstanding (Diluted)
606059595854
Shares Change (YoY)
0.94%0.96%0.92%0.92%8.08%59.11%
EPS (Basic)
-0.45-0.56-0.94-0.64-1.06-1.07
EPS (Diluted)
-0.45-0.56-0.94-0.64-1.06-1.07
Shares Outstanding
60.3260.1659.6559.258.5658.08
Free Cash Flow
-25.99-33.35-43.21-30.33-56.65-42.56
Free Cash Flow Per Share
-0.43-0.56-0.73-0.51-0.97-0.79
EBITDA
-28.13-35.01-59.87-42.53-62.42-55.96
EBIT
-28.38-35.27-60.12-42.79-62.68-56.22
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q